Edition:
United Kingdom

Celgene Corp (CELG.OQ)

CELG.OQ on NASDAQ Stock Exchange Global Select Market

77.73USD
18 Jun 2018
Change (% chg)

$-0.35 (-0.45%)
Prev Close
$78.08
Open
$77.46
Day's High
$78.07
Day's Low
$76.92
Volume
2,626,824
Avg. Vol
2,449,215
52-wk High
$147.13
52-wk Low
$74.14

Select another date:

Fri, May 4 2018

Celgene profit tops estimates; clarifies path for key MS drug

Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

UPDATE 3-Celgene profit tops estimates; clarifies path for key MS drug

May 4 Celgene Corp reported much-needed, stronger-than-expected first quarter results as profit and sales of several drugs exceeded Wall Street forecasts, and the U.S. biotechnology company said it would re-apply for approval of an important multiple sclerosis treatment in early 2019.

CORRECTED-UPDATE 2-Celgene tops estimates on higher demand for cancer drug Revlimid

* To resubmit ozanimod marketing application earlier than expected

BRIEF-Celgene Reports Q1 Adjusted Earnings Per Share Of $2.05

* CELGENE REPORTS FIRST QUARTER 2018 OPERATING AND FINANCIAL RESULTS

Celgene's quarterly profit dips 9 percent

May 4 Celgene Corp's quarterly profit fell about 9 percent despite the U.S. biotech reporting higher revenue, as its expenses surged.

BRIEF-Celgene Corp Entered Into An Amended And Restated Credit Agreement

* CELGENE CORP - ENTERED INTO AN AMENDED AND RESTATED CREDIT AGREEMENT TO EXTEND TERM OF CREDIT FACILITY TO APRIL 25, 2023 FROM APRIL 17, 2022 Source text (https://bit.ly/2HCsgr2) Further company coverage:

BRIEF-Celgene Corp Says CEO Mark Alles's FY 2017 Total Compensation Was $13.1 Mln Vs $12.2 Mln In FY 2016

* CELGENE CORP SAYS CEO MARK ALLES'S FY 2017 TOTAL COMPENSATION WAS $13.1 MILLION VERSUS $12.2 MILLION IN FY 2016 - SEC FILING

BRIEF-Zymeworks And Celgene Expand Bispecific Antibody Collaboration

* ZYMEWORKS AND CELGENE EXPAND BISPECIFIC ANTIBODY COLLABORATION

BRIEF-Celgene Announces Changes To Its Board Of Directors

* CELGENE CORPORATION ANNOUNCES CHANGES TO ITS BOARD OF DIRECTORS

Celgene Chief Operating Officer Scott Smith abruptly resigns

Celgene Corp said on Monday Chief Operating Officer Scott Smith is leaving the company, effective immediately.

Select another date: